EGFP mRNA (Cap-1; mo⁵U)

EGFP mRNA (Cap-1; mo⁵U) encodes enhanced GFP (EGFP), a variant of A. victoria GFP that contains chromophore mutations that increase the sensitivity of the protein and displays excitation and emission maxima of 489 and 511 nm, respectively.¹ It is capped using a co-transcriptional capping method, resulting in the naturally occurring Cap 1 structure with high capping efficiency. EGFP mRNA is also polyadenylated and modified with 5-methoxy-UTP (mo⁵U) to inhibit RNA-mediated innate immune activation. Encapsulation of EGFP mRNA (Cap-1; mo⁵U) in lipid nanoparticles (LNPs) can be used for mRNA delivery and expression of EGFP in vitro or in vivo.^2,3

WARNING This product is not for human or veterinary use.

1. Zhang, G., Gurtu, V., and Kain, S.R. An enhanced green fluorescent protein allows sensitive detection of gene transfer in mammalian cells. Biochem. Biophys. Res. Commun. 227(3), 707-711 (1996).

2. Huang, Y., Yang, M., Wang, N., et al. Intracellular delivery of messenger RNA to macrophages with surfactant-derived lipid nanoparticles. Materials Today Advances 16, 100295 (2022).

3. Li, M., Huang, Y., Wu, J., et al. A PEG-lipid-free COVID-19 mRNA vaccine triggers robust immune responses in mice. Mater. Horiz. 10(2), 466-472 (2023).